TargetBeta
VTCN1
V-set domain containing T cell activation inhibitor 1 · also B7-H4, FLJ22418, B7S1, B7x · V-set domain containing
5 programs in company-led studies act on VTCN1, from 5 companies: 3 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| mocertatug rezetecan | GlaxoSmithKline | phase 3 | 1111 running | – | the company's pipeline |
| Anti-B7-H4 Antibody Drug Conjugate BG-C9074rule | BeOne Medicines | phase 3 | 22 running | – | NCIt |
| puxitatug samrotecan | AstraZeneca | phase 3 | 22 running | – | a judged reading |
| Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103rule | ABL Bio | phase 2 | 22 running | TNFRSF9 | NCIt |
| Anti-B7-H4/MMAE ADC LNCB74rule | LigaChem Biosciences | phase 1 | 11 running | – | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Endometrial Neoplasms, 2 programs
- Ovarian Neoplasms, 2 programs
- Breast Neoplasms, 1 program
- Carcinoma, Ovarian Epithelial, 1 program
- Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 7, 2027mocertatug rezetecan · GlaxoSmithKline · phase 3 · NCT06855069
- Sep 28, 2027Anti-B7-H4 Antibody Drug Conjugate BG-C9074 · BeOne Medicines · phase 3 · NCT06233942
- Sep 29, 2027puxitatug samrotecan · AstraZeneca · phase 3 · NCT05123482
- Dec 2027Anti-B7-H4/MMAE ADC LNCB74 · LigaChem Biosciences · phase 1 · NCT06774963
- Dec 2, 2027Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103 · ABL Bio · phase 2 · NCT07158918
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.